This is smart use of smallish cash upfront, to get a very big "fisheye lens / periscope" look -- at C4's aptly named "torpedo" platforms, and their potential use in immuno-oncology.
The deal will be very lucrative for C4, in a few years, if even one of the torpedos arms itself, and shows efficacy in a clinical trial. But it is firmly pre-clinical at this point.
Still very much a good news / potential future diversifying revenue stream for Rahway into the next decades. Here's the latest, this morning:
. . .C4 Therapeutics shares jumped 50% premarket on Tuesday after it forged an exclusive license deal with Merck to develop its degrader-antibody conjugates (DACs) for certain cancer targets. . . .
Merck will be responsible for antibody conjugation to create DACs in the discovery phase and for advancing these DAC candidates through preclinical and clinical development as well as commercialization.
C4 Therapeutics (CCCC) will receive a $10M upfront payment plus milestone payments ~$600M for DACs directed to the initial oncology target. The company will also earn tiered royalties on future sales.
Merck will have an option to extend the collaboration to include three additional targets that would be exclusive to the collaboration, which. . . could result in payments of ~$2.5 billion to C4, across the collaboration, eventually. . . .
Now you know -- onward and grinning -- into the very crisp sunshine this morning -- as Harvard's board votes to keep its president, despite the GOP distraction tours / silly House crisis actors, now trolling the Congress.
नमस्ते
No comments:
Post a Comment